webinar register page

Webinar banner
CDDF webinar: MRD by NGS in patients with AML undergoing allogeneic transplantation
The Cancer Drug Development Forum holds a webinar “MRD by NGS in patients with AML undergoing allogeneic transplantation” on Thursday 24 February 2022 at 17:00 - 18:00 CET.

This webinar comprises a lecture given by Dr. Christopher Hourigan (Myeloid Malignancies, NIH, US), followed by a discussion session moderated by Prof. Axel Glasmacher (CDDF, DE) and Prof. John Smyth (CDDF, UK).

Feb 24, 2022 05:00 PM in Brussels

Webinar logo
* Required information


Christopher Hourigan
Dr. @The National Institutes of Health (NIH)
Dr. Christopher Hourigan DM DPhil FACP FRCP is Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). He is co-director of the trans-NIH Myeloid Malignancies Program, part-time Associate Professor of Oncology at Johns Hopkins School of Medicine, and a member of the Leukemia program of Johns Hopkins Hospital. Dr. Hourigan’s research focuses measurable residual disease (MRD) in acute myeloid leukemia (AML). He is co-PI of the upcoming fNIH Industry-FDA-Academic-NIH biomarkers consortium on AML MRD.